[{"id":"39e235cc-f722-49ca-9587-b49d0cd81c0b","acronym":"REFLECTIONS B328-06t","url":"https://clinicaltrials.gov/study/NCT02213263","created_at":"2021-01-18T10:22:05.259Z","updated_at":"2024-07-02T16:36:58.739Z","phase":"Phase 3","brief_title":"A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)","source_id_and_acronym":"NCT02213263 - REFLECTIONS B328-06t","lead_sponsor":"Pfizer","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Ruxience (rituximab-pvvr)"],"overall_status":"Completed","enrollment":" Enrollment 394","initiation":"Initiation: 09/30/2014","start_date":" 09/30/2014","primary_txt":" Primary completion: 10/23/2017","primary_completion_date":" 10/23/2017","study_txt":" Completion: 04/19/2018","study_completion_date":" 04/19/2018","last_update_posted":"2019-06-20"}]